肝脏 ›› 2020, Vol. 25 ›› Issue (10): 1068-1071.

• 肝癌 • 上一篇    下一篇

肝细胞癌与混合型肝细胞胆管细胞癌临床特征及预后观察

侯庆柱, 熊静平, 彭媛媛   

  1. 810000 西宁 青海省第五人民医院消化内科(侯庆柱); 新疆医科大学第七附属医院消化内科(熊静平); 新疆医科大学第二附属医院消化一科(彭媛媛)
  • 收稿日期:2020-04-21 出版日期:2020-10-31 发布日期:2020-12-18
  • 基金资助:
    新疆医科大学科研创新基金项目(XYDCX201517)

The clinical characteristics and prognosis of hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma

HOU Qing-zhu, XIONG Jing-ping, PENG Yuan-yuan   

  1. Department of Gastroenterology, the Fifth People's Hospital of Qinghai Province, Xining 810000, China
  • Received:2020-04-21 Online:2020-10-31 Published:2020-12-18

摘要: 目的 探讨肝细胞癌(HCC)与混合型肝细胞胆管细胞癌(cHCC-CC)的临床特征以及预后情况。方法 纳入我院2014年12月—2017年12月收治的HCC、cHCC-CC患者各60例,分别作为HCC组、cHCC-CC组,收集两组患者的临床资料。于入院当日采集2 mL肘静脉血,测定血清糖类抗原19-9(CA19-9)、癌胚抗原(CEA)水平,绘制受试者工作特征曲线(ROC)分析相关指标对HCC、cHCC-CC的鉴别价值,并比较两组2年的预后情况。结果 cHCC-CC组的局部浸润、肝内胆管扩张、累及门静脉、肿瘤包膜占比显著高于HCC组(P<0.05)。cHCC-CC组血清CA19-9水平显著高于HCC组(P<0.05),两组血清CEA含量比较无差异(P>0.05)。血清CA19-9鉴别cHCC-CC、HCC的曲线下面积为0.735(标准误=0.046,P=0.000,95%CI=0.644~0.825),最佳界值为215.400mIu/L。随访2年,提示两组无瘤生存率比较无差异(P>0.05),cHCC-CC组总生存率显著低于HCC组(P<0.05)。结论 HCC、cHCC-CC患者的局部浸润、肝内胆管扩张、累及门静脉、肿瘤包膜情况存在差别,且血清CA19-9可作为鉴别二者的重要指标,其中cHCC-CC患者的预后相对较差。

关键词: 混合型肝细胞胆管细胞癌, 肝细胞癌, 肝内胆管扩张, 肿瘤包膜, 预后

Abstract: Objective To investigate the clinical characteristics and prognosis of hepatocellular carcinoma (HCC) and combined hepatocellular-cholangiocarcinoma (cHCC-CC). Methods From December 2014 to December 2017, 60 patients with HCC and 60 patients with cHCC-CC in our hospital were enrolled as HCC group and cHCC-CC group. The clinical data of the patients were collected. On the day of admission, 2 ml of elbow vein blood was collected to examine the levels of carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA). The receiver operating characteristic (ROC) curve was drawn to evaluate the value of related indexes in differential diagnosis for HCC and cHCC-CC. And the 2-year prognosis was compared between the 2 groups. Results The proportions of local infiltration, intrahepatic biliary ductal dilatation, portal vein involvement and tumor capsule in cHCC-CC group were significantly higher than those in HCC group (P<0.05). Serum CA19-9 level in cHCC-CC group was significantly higher than that in HCC group (P<0.05). There was no difference in serum CEA level between the 2 groups (P>0.05). The area under the ROC curve of serum CA19-9 for the identification of cHCC-CC and HCC was 0.735 (standard error = 0.046, P=0.000, 95% confidence interval = 0.644 ~ 0.825), and the optimal cut-off was 215.400 mIu/L. There was no significant difference in the 2-year tumor-free survival rate between the 2 groups (P>0.05). And the overall survival rate in the cHCC-CC group was significantly lower than that in the HCC group (P<0.05). Conclusion There were significant differences in the rates of local infiltration, intrahepatic biliary ductal dilatation, portal vein involvement and tumor capsule between HCC and cHCC-CC patients. And serum CA19-9 can be used as an important indicator to distinguish them. The prognosis of cHCC-CC patients is relatively poor.

Key words: Combined hepatocellular-cholangiocarcinoma, Hepatocellular carcinoma, Intrahepatic biliary ductal dilatation, Tumor capsule, Prognosis